Eltrombopag (Revolade®) in cases of severe aplastic anaemia
The National Health Care Institute has approved a pharmacotherapeutic report for the medicine eltrombopag (Revolade®) in cases of severe aplastic anaemia. They reached the following conclusion.
Eltrombopag, together with best supportive care, has an added therapeutic value in comparison with best supportive care for patients with refractory aplastic anaemia who are not eligible for haematopoietic stem cell transplantation.